Consequently, a modular phase I/1b study is ongoing evaluating increasing doses of ceralasertib in combination with carboplatin, olaparib, or durvalumab in patients with advanced malignancies, including BRCA-mutant, RAD51C/D-mutant or HRD-positive status PSR ovarian cancer patients who have previously progressed on a licensed PARP-i (NCT02264678). This evidence concerns the gene PARP1 and ovarian carcinoma.